HC Wainwright reiterated their buy rating on shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) in a research report sent to investors on Sunday. They currently have a $12.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on AEZS. Maxim Group reaffirmed a buy rating and set a $11.00 price target on shares of Aeterna Zentaris in a research report on Tuesday, August 2nd. Zacks Investment Research raised shares of Aeterna Zentaris from a hold rating to a buy rating and set a $4.00 price target on the stock in a research report on Monday, August 15th. Finally, Canaccord Genuity reaffirmed a buy rating and set a $9.00 price target on shares of Aeterna Zentaris in a research report on Tuesday, August 23rd.

Shares of Aeterna Zentaris (NASDAQ:AEZS) opened at 3.50 on Friday. The firm’s market capitalization is $34.79 million. Aeterna Zentaris has a 12 month low of $2.60 and a 12 month high of $15.70. The stock’s 50 day moving average is $3.79 and its 200 day moving average is $3.56.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

5 Day Chart for NASDAQ:AEZS

Receive News & Stock Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related stocks with our FREE daily email newsletter.